Biomarkers in Patients with Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers

Article

This clinical trial is analyzing biomarkers in patients with respiratory tract dysplasia or lung cancer, head and neck cancer, or aerodigestive tract cancer and in normal volunteers.

Study Type: Observational

Age/Sex Requirement: None

Sponsor: University of Colorado at Denver and Health Sciences Center

Clinicaltrials.gov Identifier: NCT00900419

Purpose: To evaluate biomarkers in patients with respiratory tract dysplasia or lung cancer, head and neck cancer, or aerodigestive tract cancer and in normal volunteers. The primary outcome measure is genetic mutations or altered growth factor expression. The secondary outcome measure is the establishment of a tissue repository of normal and dysplastic respiratory epithelium.

Click here to access additional information from this third-party website.

Related Videos
Elna Saah, MD: Unraveling the Current Landscape of Sickle Cell Disease | Image Credit: Twitter
Insight on the Promising 52-Week KarXT Data with Rishi Kakar, MD
Jonathan Barratt, MD | Credit: IgA Nephropathy Foundation
HCPLive Five at ACC 2024 | Image Credit: HCPLive
Jonathan Barratt, MD | Credit: IgA Nephropathy Foundation
Sunny Rai, PhD: “I” Language Markers Do Not Detect Depression in Black Individuals
© 2024 MJH Life Sciences

All rights reserved.